Comparative Pharmacology
Head-to-head clinical analysis: ABACAVIR DOLUTEGRAVIR LAMIVUDINE versus EMTRIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABACAVIR DOLUTEGRAVIR LAMIVUDINE versus EMTRIVA.
ABACAVIR || DOLUTEGRAVIR || LAMIVUDINE vs EMTRIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Abacavir is a carbocyclic synthetic nucleoside analog guanosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase. Dolutegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks viral integration into host DNA. Lamivudine is a synthetic nucleoside analog cytosine reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
One tablet (600 mg abacavir, 50 mg dolutegravir, 300 mg lamivudine) orally once daily.
Emtricitabine 200 mg orally once daily.
None Documented
None Documented
Abacavir: 1.5 hr (terminal half-life ~1.5 hr, but intracellular carbovir-TP half-life ~12-20 hr supports once-daily dosing). Dolutegravir: ~14 hr (terminal half-life, clinical context: once-daily dosing due to long intracellular half-life and high potency). Lamivudine: 5-7 hr (terminal half-life, intracellular half-life of lamivudine-TP ~18-22 hr supports once-daily dosing).
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Abacavir: 83% renal (primarily as metabolites via alcohol dehydrogenase and glucuronidation), 16% fecal. Dolutegravir: 64% fecal (unchanged), 32% renal (minor as metabolites via UGT1A1 and CYP3A4). Lamivudine: >70% renal (unchanged via organic cation transport).
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Category A/B
Category C
NRTI
Antiretroviral, NRTI